Published in Antimicrob Agents Chemother on December 01, 1984
Pharmacokinetics and tissue penetration of carumonam, a new synthetic monobactam. Antimicrob Agents Chemother (1985) 1.06
Pharmacokinetics of carumonam in patients with renal insufficiency. Antimicrob Agents Chemother (1986) 1.01
Disposition of carumonam (AMA-1080/Ro 17-2301), a new N-sulfonated monocyclic beta-lactam, in rats and dogs. Antimicrob Agents Chemother (1986) 0.87
Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother (1986) 0.86
Carumonam (Ro 17-2301; AMA-1080) compared with gentamicin for treatment of complicated urinary tract infections. Antimicrob Agents Chemother (1988) 0.85
Susceptibility testing of carumonam: interpretive criteria for 30-microgram disk tests and quality control guidelines for disk diffusion and broth microdilution methods. J Clin Microbiol (1987) 0.82
Comparative in vitro antimicrobial activity of carumonam, a new monocyclic beta-lactam. Antimicrob Agents Chemother (1986) 0.82
Pharmacokinetics of carumonam after single and multiple 1- and 2-g dosage regimens. Antimicrob Agents Chemother (1988) 0.80
Pharmacokinetics of carumonam (AMA-1080) in patients with impaired renal function and in those undergoing hemodialysis. Antimicrob Agents Chemother (1991) 0.75
Mechanism of renal excretion of carumonam in rats, rabbits, dogs, and monkeys. Antimicrob Agents Chemother (1987) 0.75
Sulfazecin and isosulfazecin, novel beta-lactam antibiotics of bacterial origin. Nature (1981) 2.84
Monobactams--monocyclic beta-lactam antibiotics produced by bacteria. J Antimicrob Chemother (1981) 2.68
Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci (1979) 1.56
Disposition kinetics of ethambutol in man. J Pharmacokinet Biopharm (1980) 1.50
Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science (1998) 5.62
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol (2000) 3.04
Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther (1981) 2.93
Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol (1983) 2.45
Pheochromocytomas: can malignant potential be predicted? Urology (1999) 2.23
Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet (2001) 1.91
Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittelforschung (1981) 1.71
Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans. Antimicrob Agents Chemother (1988) 1.64
Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. Chemotherapy (1981) 1.59
Single-dose pharmacokinetics of ceftriaxone in infants and young children. Antimicrob Agents Chemother (1982) 1.59
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res (1999) 1.57
Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull World Health Organ (1982) 1.57
Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther (1995) 1.53
Purification of nerve growth factor antibodies by affinity chromatography. J Neurochem (1976) 1.49
Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms tumors: expression at the mRNA and protein level. Proc Natl Acad Sci U S A (1987) 1.47
Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects. Antimicrob Agents Chemother (1989) 1.41
Sodium-volume factor, cardiovascular reactivity and hypotensive mechanism of diuretic therapy in mild hypertension associated with diabetes mellitus. Am J Med (1979) 1.30
Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose. Eur J Clin Pharmacol (1982) 1.27
An antigenic polypeptide fragment isolated from tetanus toxin: chemical characterization, binding to gangliosides and retrograde axonal transport in various neuron systems. J Neurochem (1977) 1.26
Randomized treatment of patients with typhoid fever by using ceftriaxone or chloramphenicol. J Infect Dis (1988) 1.24
Capillary exchange modeling. Barrier-limited and flow-limited distribution. Circ Res (1970) 1.24
Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. Br J Clin Pharmacol (1983) 1.22
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res (1998) 1.21
Transcapillary exchange in the working left ventricle of the dog. Circ Res (1971) 1.20
Bioavailability from various galenic formulations of flunitrazepam. Arzneimittelforschung (1977) 1.19
Kinetics of rubidium uptake in the working dog heart. Circ Res (1971) 1.19
Alpha and beta adrenergic blockade with orally administered labetalol in hypertension. Studies on blood volume, plasma renin and aldosterone and catecholamine excretion. Am J Cardiol (1978) 1.19
Specificity of retrograde transport of nerve growth factor (NGF) in sensory neurons: a biochemical and morphological study. Brain Res (1975) 1.17
A new sensitive, rapid fluorescence technique for the determination of proteins in gel electrophoresis and in solution. Anal Biochem (1973) 1.17
Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy. Eur J Clin Pharmacol (1986) 1.12
Hydrophobic binding sites in bovine serum albumin and erythrocyte ghost proteins. Study by spin-labelling, paramagnetic fluorescence quenching and chemical modification. Biochim Biophys Acta (1974) 1.09
Biological importance of retrograde axonal transport of nerve growth factor in adrenergic neurons. Brain Res (1975) 1.09
Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung (1979) 1.08
Screening methods using sulfamethazine for determining acetylator phenotype. Clin Pharmacol Ther (1979) 1.06
Erythrocyte membrane alterations due to infection with Plasmodium berghei. Biochim Biophys Acta (1973) 1.06
Role of gangliosides in the uptake and retrograde axonal transport of cholera and tetanus toxin as compared to nerve growth factor and wheat germ agglutinin. Brain Res (1977) 1.05
Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations. Eur J Clin Pharmacol (1983) 1.05
Retrograde axonal transport of nerve growth factor: specificity and biological importance. Brain Res (1975) 1.05
Age-associated changes in ceftriaxone pharmacokinetics. Clin Pharmacokinet (1986) 1.04
Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br J Clin Pharmacol (1983) 1.03
Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics. Clin Pharmacokinet (1983) 1.02
Effects of timing of food and fluid volume on cefetamet pivoxil absorption in healthy normal volunteers. Antimicrob Agents Chemother (1990) 1.01
[Relationship between clinical effects and pharmacokinetics of midazolam on i.m. and i.v. application to volunteers/1st comm.: Clinical aspects (author's transl)]. Arzneimittelforschung (1981) 1.01
Sodium, renin, aldosterone, catecholamines, and blood pressure in diabetes mellitus. Kidney Int (1977) 1.01
Pharmacokinetics of carumonam in patients with renal insufficiency. Antimicrob Agents Chemother (1986) 1.01
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol (1999) 0.99
New analogs of trimethoprim. Rev Infect Dis (1982) 0.97
Influence of antacid and ranitidine on the pharmacokinetics of oral cefetamet pivoxil. Antimicrob Agents Chemother (1990) 0.97
Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration. Br J Clin Pharmacol (1986) 0.96
Pharmacokinetics of cefetamet pivoxil (Ro 15-8075) with ascending oral doses in normal healthy volunteers. Antimicrob Agents Chemother (1989) 0.96
Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. Chemotherapy (1987) 0.95
Assay and pharmacokinetics of trimethoprim in man and animals. Postgrad Med J (1969) 0.95
The significance of retrograde axonal transport for the accumulation of systemically administered nerve growth factor (NGF) in the rat superior cervical ganglion. Brain Res (1976) 0.95
Influence of maturation and growth on cefetamet pivoxil pharmacokinetics: rational dosing for infants. Antimicrob Agents Chemother (1996) 0.94
Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. Antimicrob Agents Chemother (1990) 0.94
The study of lipid-protein interactions in membranes by fluorescent probes. Biochim Biophys Acta (1970) 0.93
Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother (2009) 0.92
Biotransformation of moclobemide in humans. Acta Psychiatr Scand Suppl (1990) 0.92
Raman and infrared spectroscopic study of gramicidin A conformations. Arch Biochem Biophys (1980) 0.92
Hypertension associated with tumors adjacent to renal arteries. Am J Med (1969) 0.91
The pathogenesis of tumour hypoglycaemia: blocks of hepatic glucose release and of adipose tissue lipolysis. Diabetologia (1967) 0.91
Single-dose ceftriaxone kinetics in liver insufficiency. Clin Pharmacol Ther (1984) 0.91
Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency. Antimicrob Agents Chemother (1989) 0.91
Age versus urinary sodium for judging renin, aldosterone, and catecholamine levels: studies in normal subjects and patients with essential hypertension. Kidney Int (1978) 0.91
Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology (1989) 0.90
Bioavailability of syrup and tablet formulations of cefetamet pivoxil. Antimicrob Agents Chemother (1993) 0.90
Pharmacokinetics of ceftriaxone in neonates and infants with meningitis. J Pediatr (1984) 0.89
Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. Chemotherapy (1987) 0.89
Protein binding of ceftriaxone in extravascular fluids. J Pharm Sci (1988) 0.89
Plasma concentrations of sulfadoxine in healthy and malaria infected Thai subjects. Acta Trop (1988) 0.89
[Relation between the clinical effect and the pharmacokinetics of midazolam following i.m. and i.v. administration/2nd comm.: Pharmacokinetical aspects (author's transl)]. Arzneimittelforschung (1981) 0.89
Single-dose ceftriaxone kinetics in functionally anephric patients. Clin Pharmacol Ther (1983) 0.88
Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm (1992) 0.88
Cefetamet pivoxil: a review of its microbiology, toxicology, pharmacokinetics and clinical efficacy. Int J Antimicrob Agents (1992) 0.88
Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol (1999) 0.87
Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in children. Antimicrob Agents Chemother (1991) 0.87
Single-dose ceftriaxone kinetics in the newborn. Clin Pharmacol Ther (1985) 0.87
Effect of long-term physical exercise on lymphocyte reactivity: similarity to spaceflight reactions. Aviat Space Environ Med (1988) 0.87
Lack of effect of the benzodiazepine antagonist flumazenil (Ro 15-1788) on the performance of healthy subjects during experimentally induced ethanol intoxication. Eur J Clin Pharmacol (1988) 0.87
Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1989) 0.87
Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. Am J Med (1984) 0.86
Catecholamines, sodium and renin in unilateral renal hypertension in man. Miner Electrolyte Metab (1982) 0.86
Fleroxacin: a review of its chemistry, microbiology, toxicology, pharmacokinetics, clinical efficacy and safety. Int J Antimicrob Agents (1993) 0.85
Fraction unbound in interstitial fluid. J Pharm Sci (1983) 0.85
Increased ratio between changes in blood pressure and plasma norepinephrine in essential hypertension. J Clin Endocrinol Metab (1979) 0.85
Extraction and localization of a (Ca2+ and Mg2+)-stimulated ATPase in human erythrocyte spectrin. Biochim Biophys Acta (1975) 0.85
Penetration of fleroxacin into human and animal tissues. Chemotherapy (1992) 0.84
Raman spectroscopic investigation of the interaction of gramicidin A with dipalmitoyl phosphatidylcholine liposomes. Biochim Biophys Acta (1977) 0.84
Pressor factors and cardiovascular pressor responsiveness in borderline hypertension. Hypertension (1981) 0.84
A reversible form of apical left ventricular hypertrophy associated with pheochromocytoma. J Am Soc Echocardiogr (1993) 0.84
Stimulation of aldosterone biosynthesis in vitro by serotonin. Acta Endocrinol (Copenh) (1968) 0.84
Cefetamet pivoxil clinical pharmacokinetics. Clin Pharmacokinet (1993) 0.83
Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam. Biochem Pharmacol (1990) 0.83
Effect of a herbal yeast food supplement and long-distance running on immunological parameters. Br J Sports Med (1990) 0.83
Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration. J Clin Pharmacol (1996) 0.83